The closest thing we have to an HIV vaccine has hit the market – but less than a tenth of the doses needed to change the course of the pandemic will reach the people who need them, new figures suggest.
A plan between the drug company Gilead and international funders to give two million people the long-acting jab lenacapavir across three years – or 666,000 a year – will only avert up to 165,000 infections, which “just isn't enough”, said Dr Andrew Hill of the University of Liverpool. His research has found that getting 10 million people a year the jab could avoid half a million HIV infections and “start putting us on a course towards ending HIV transmission”.
